FC receptor (FcRn) binding peptides and uses thereof

Patent metadata

Field	Value
Publication number	US-10588935-B2
Application number	US-201916293879-A
Country	US
Kind code	B2
Filing date	Mar 6, 2019
Priority date	Jun 18, 2013
Publication date	Mar 17, 2020
Grant date	Mar 17, 2020

Abstract

The invention provided herein includes isolated polypeptides that specifically block the interaction between neonatal Fc receptor (FcRn) and albumin. Blocking the interaction treats diseases and conditions caused by increased amounts of albumin or modified albumin that possesses pathogenic properties wherein it is deemed desirable to decrease albumin levels. Accordingly, also provided are methods of using these isolated polypeptides to treat various diseases and conditions caused by increased amounts of albumin or modified albumin that possesses pathogenic properties. The invention provided herein also includes isolated polypeptides capable of binding to a non-IgG and non-albumin competitive site on an FcRn alpha 3 domain. These can be useful for tracking FcRn without inhibiting IgG or albumin binding or function. Accordingly, the invention also includes methods and systems to track FcRn without inhibiting IgG or albumin binding or function.

First claim

What is claimed is:

1. A nucleic acid encoding a polypeptide that specifically blocks the interaction between neonatal Fc receptor (FcRn) and albumin, said polypeptide comprising at least one subunit comprising an amino acid sequence at least 90% identical to the amino acid sequence RYFCTKWKHGWCEEVGT (SEQ ID NO:1), wherein the subunit is up to 20 amino acids in length.

2. The nucleic acid encoding a polypeptide of claim 1 , wherein the polypeptide comprises two to four peptide subunits.

3. A vector comprising the nucleic acid according to claim 1 .

4. A vector comprising the nucleic acid according to claim 2 .

5. A cell comprising the vector according to claim 3 .

6. A cell comprising the vector according to claim 4 .

7. A cell comprising the nucleic acid according to claim 1 .

8. A cell comprising the nucleic acid according to claim 2 .

9. An isolated polypeptide capable of binding to a non-IgG and non-albumin competitive site on a FcRn alpha 3 domain comprising the amino acid sequence selected from SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6.

10. A composition comprising the isolated polypeptide of claim 9 .

11. A nucleic acid encoding an isolated polypeptide of claim 9 .

12. A vector comprising the nucleic acid of claim 11 .

13. A cell comprising the nucleic acid according to claim 11 .

14. A cell comprising the vector according to claim 12 .

Assignees

• Brigham & Womens Hospital Inc
• Biogen Ma Inc

Inventors

• Blumberg Richard S
• Rath Timo
• Baker Kristi
• Mezo Adam
• Taylor Zachary
• Mcdonnell Kevin
• Grenha Rosa Maria Silva Garcia

Classifications

• C07K14/001

  by chemical synthesis · CPC title

• C07K2319/31

  fusions, other than Fc, for prolonged plasma life, e.g. albumin · CPC title

• C07K14/765

  Serum albumin, e.g. HSA · CPC title

• G01N33/5023

  on expression patterns · CPC title

• C12N15/1037

  Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display · CPC title